Winnie Sohn

2.1k total citations · 2 hit papers
26 papers, 1.5k citations indexed

About

Winnie Sohn is a scholar working on Oncology, Rheumatology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Winnie Sohn has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Rheumatology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Winnie Sohn's work include Bone health and treatments (10 papers), Lipoproteins and Cardiovascular Health (5 papers) and Systemic Lupus Erythematosus Research (5 papers). Winnie Sohn is often cited by papers focused on Bone health and treatments (10 papers), Lipoproteins and Cardiovascular Health (5 papers) and Systemic Lupus Erythematosus Research (5 papers). Winnie Sohn collaborates with scholars based in United States, France and Australia. Winnie Sohn's co-authors include Susie Jun, Robert M. Henshaw, Sant P. Chawla, Arthur P. Staddon, J. W. G. Smith, Martine P. Roudier, Roger Dansey, Jean‐Yves Blay, Keith M. Skubitz and David M. Thomas and has published in prestigious journals such as Circulation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Winnie Sohn

26 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

2010 516 citations David M. Thomas, Robert M. Henshaw et al. The Lancet Oncology profile →
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

2022 167 citations Michael J. Koren, Patrick M. Moriarty et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Winnie Sohn United States	13	686	603	510	324	315	26	1.5k
Béatrice Marie France	19	368 0.5×	316 0.5×	443 0.9×	178 0.5×	159 0.5×	48	1.3k
Anna Maria Frezza Italy	22	759 1.1×	360 0.6×	764 1.5×	170 0.5×	93 0.3×	78	1.5k
Michael Rader United States	9	1.8k 2.7×	141 0.2×	1.0k 2.0×	422 1.3×	37 0.1×	20	2.4k
Guozhi Gao United States	14	802 1.2×	221 0.4×	288 0.6×	130 0.4×	15 0.0×	27	1.4k
Marilena Cesari Italy	20	334 0.5×	493 0.8×	882 1.7×	227 0.7×	81 0.3×	63	1.1k
Anne‐Valérie Decouvelaere France	23	543 0.8×	462 0.8×	1.1k 2.1×	212 0.7×	172 0.5×	42	1.6k
Richard H. De Boer Australia	15	1.7k 2.5×	107 0.2×	669 1.3×	297 0.9×	28 0.1×	48	2.1k
Eirini Katodritou Greece	24	1.4k 2.1×	149 0.2×	148 0.3×	102 0.3×	33 0.1×	108	2.5k
Marta Barisella Italy	18	545 0.8×	500 0.8×	990 1.9×	140 0.4×	93 0.3×	60	1.2k
Umio Yamaguchi Japan	18	239 0.3×	249 0.4×	573 1.1×	154 0.5×	53 0.2×	28	1.0k

Countries citing papers authored by Winnie Sohn

Since Specialization

Citations

This map shows the geographic impact of Winnie Sohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Winnie Sohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Winnie Sohn more than expected).

Fields of papers citing papers by Winnie Sohn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Winnie Sohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Winnie Sohn. The network helps show where Winnie Sohn may publish in the future.

Co-authorship network of co-authors of Winnie Sohn

This figure shows the co-authorship network connecting the top 25 collaborators of Winnie Sohn. A scholar is included among the top collaborators of Winnie Sohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Winnie Sohn. Winnie Sohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kroenke, Mark A., et al.. (2025). Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studies. Journal of Immunological Methods. 540. 113864–113864. 3 indexed citations

O’Donoghue, Michelle L., Robert S. Rosenson, J. Antonio G. López, et al.. (2024). The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering. Journal of the American College of Cardiology. 84(9). 790–797. 27 indexed citations

Sohn, Winnie, et al.. (2022). Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study. Clinical Therapeutics. 44(9). 1237–1247. 25 indexed citations

Xing, Changying, Jing Chen, Li Zuo, et al.. (2021). A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis. Clinical Therapeutics. 43(11). 2013–2023. 1 indexed citations

Trivedi, Ashit, Winnie Sohn, Priyanka Kulkarni, et al.. (2021). Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model. Clinical and Translational Science. 14(6). 2510–2520. 9 indexed citations

Koren, Michael J., Patrick M. Moriarty, Joel Neutel, et al.. (2020). Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a). Circulation. 142(Suppl_3). 25 indexed citations

Janiszewski, Mariano, et al.. (2019). A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING SINGLE-DOSE, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AMG 529, A NOVEL ANTI-ASGR1 MONOCLONAL ANTIBODY, IN HEALTHY SUBJECTS. Journal of the American College of Cardiology. 73(9). 1755–1755. 7 indexed citations

Chen, Ping, et al.. (2019). Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet. British Journal of Clinical Pharmacology. 85(6). 1312–1325. 6 indexed citations

Sohn, Winnie, Edward Lee, Martin Kankam, et al.. (2015). An open‐label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners. British Journal of Clinical Pharmacology. 81(2). 362–369. 7 indexed citations

10.

Martinꝉ, Roland, Zahir Amoura, Juanita Romero‐Díaz, et al.. (2015). THU0389 A Multiple Dose Study of AMG 811 (Anti-IFN-Gamma) in Subjects with Systemic Lupus Erythematosus and Active Nephritis. Annals of the Rheumatic Diseases. 74. 337–337. 10 indexed citations

11.

Welcher, Andrew A., Michael Boedigheimer, Alan Kivitz, et al.. (2015). Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 67(10). 2713–2722. 55 indexed citations

12.

Chen, Ping, Thuy Vu, Winnie Sohn, et al.. (2014). Pharmacokinetic and Pharmacodynamic Relationship of AMG 811, An Anti-IFN-γ IgG1 Monoclonal Antibody, in Patients with Systemic Lupus Erythematosus. Pharmaceutical Research. 32(2). 640–653. 38 indexed citations

13.

Block, Geoffrey A., Ogo Egbuna, Steven Zeig, et al.. (2014). The evaluation of denosumab safety in patients with chronic kidney disease: An open-label study.. Journal of Clinical Oncology. 32(15_suppl). e20649–e20649. 5 indexed citations

14.

Sohn, Winnie, et al.. (2014). The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review. British Journal of Clinical Pharmacology. 78(3). 477–487. 43 indexed citations

15.

Block, Geoffrey A., Ogo Egbuna, Steven Zeig, et al.. (2014). Safety of Denosumab (Dmab) in Patients (Pts) with Stage 4 or Stage 5D Chronic Kidney Disease (Ckd). Annals of Oncology. 25. iv528–iv528. 2 indexed citations

16.

Gibiansky, Leonid, Liviawati Sutjandra, Sameer Doshi, et al.. (2012). Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours. Clinical Pharmacokinetics. 51(4). 247–260. 69 indexed citations

17.

Doshi, Sameer, Liviawati Sutjandra, Jenny Zheng, et al.. (2012). Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors. Clinical Cancer Research. 18(9). 2648–2657. 26 indexed citations

18.

Thomas, David M., Robert M. Henshaw, Keith M. Skubitz, et al.. (2010). Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. The Lancet Oncology. 11(3). 275–280. 516 indexed citations breakdown →

19.

Fizazi, Karim, Allan Lipton, Xavier Mariette, et al.. (2009). Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates. Journal of Clinical Oncology. 27(10). 1564–1571. 388 indexed citations

20.

Yonemori, Kan, Yasuhiro Fujiwara, Hironobu Minami, et al.. (2008). Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer–related bone metastases. Cancer Science. 99(6). 1237–1242. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact